References 1. Bouxsein ML, Karasik D (2006) Bone geometry and skeletal fragility. Bcl-2 inhibitor Curr Osteoporos Rep 4:49–56CrossRefPubMed 2. Seeman E (2003) The structural and biomechanical basis of the gain and loss of bone strength in women

and men. Endocrinol Metab Clin North Am 32:25–38CrossRefPubMed 3. Seeman E (2003) Invited review: pathogenesis of osteoporosis. J Appl Physiol 95:2142–2151PubMed 4. Stepan JJ, Alenfeld F, Boivin G et al (2003) Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 37:227–240 5. Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702PubMed 6. Civitelli R, Gonnelli S, Zachei F et al (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274CrossRefPubMed 7. Gonnelli S, Cepollaro C, Pondrelli C et al (1997) The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J Bone

Miner Res 12:624–631CrossRefPubMed 8. Gonnelli S, Cepollaro C, Pondrelli C et al (1999) Boner turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif Tissue Int 65:359–364CrossRefPubMed 9. Iwamoto J, Takeda T, Sato Y et al (2004) Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis. Yonsei selleck Med J 45:676–682PubMed 10. Kim SW,

Park DJ, Park KS et al (2005) Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J 52:667–674CrossRefPubMed 11. Seibel MJ, Naganathan V, Barton I et al (2004) drug discovery Relationship between Methisazone pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19:323–329CrossRefPubMed 12. Bauer DC, Garnero P, Hochberg MC et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the Fracture Intervention Trial. J Bone Miner Res 21:292–299CrossRefPubMed 13. Chen P, Satterwhite JH, Licata AA et al (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962–970CrossRefPubMed 14. Delmas PD, Licata AA, Reginster JY et al (2006) Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39:237–243CrossRefPubMed 15. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. New Engl J Med 350:459–468CrossRefPubMed 16.